Literature DB >> 14646706

Femoral head resurfacing for the treatment of osteonecrosis in the young patient.

Anthony Adili1, Robert T Trousdale.   

Abstract

We reviewed the clinical and radiographic results of 29 consecutive femoral head resurfacing procedures in 28 patients with avascular necrosis done from February 1997 until April 2000. There were 18 males and 10 females with an average age of 31.6 years (range, 12-48 years). The average Harris hip score significantly improved from 48.1 points preoperatively to 79.3 points at last followup. At final followup, 17 patients (18 hips [62%]) reported feeling much better or better than they did before hemiresurfacing. The overall survivorship was 75.9% at 3 years. Eight hips (27.6%) were converted to a total hip arthroplasty (THA) at an average 18 months (range, 8-43 months) after resurfacing. The results of this study suggest that femoral head resurfacing in a young patient with ON can greatly improve symptoms. The majority of patients were satisfied with the procedure but outcomes are unpredictable with only 62.5% of patients reporting satisfaction and good pain relief at last followup. We continue to offer this procedure in young patients with large necrotic lesions with the understanding that this procedure provides somewhat unpredictable pain relief; however, hemiresurfacing avoids the negatives associated with a bearing surface.

Entities:  

Mesh:

Year:  2003        PMID: 14646706     DOI: 10.1097/01.blo.0000096815.78689.3e

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  13 in total

1.  [Early functional results with the Mayo-hip, a short stem system with metaphyseal-intertrochanteric fixation].

Authors:  R Hube; M Zaage; W Hein; H Reichel
Journal:  Orthopade       Date:  2004-11       Impact factor: 1.087

2.  Surface replacement is comparable to primary total hip arthroplasty.

Authors:  Mike S McGrath; David R Marker; Thorsten M Seyler; Slif D Ulrich; Michael A Mont
Journal:  Clin Orthop Relat Res       Date:  2008-09-16       Impact factor: 4.176

3.  Frequent femoral neck osteolysis with Birmingham mid-head resection resurfacing arthroplasty in young patients.

Authors:  Asaad Asaad; Alister Hart; Michael M Y Khoo; Kevin Ilo; Gavin Schaller; Jonathan D J Black; Sarah Muirhead-Allwood
Journal:  Clin Orthop Relat Res       Date:  2015-12       Impact factor: 4.176

Review 4.  [Surgical treatment concepts for femoral head necrosis].

Authors:  D von Stechow; P Drees
Journal:  Orthopade       Date:  2007-05       Impact factor: 1.087

5.  SAS weekly rounds: avascular necrosis.

Authors:  Thomas W Hamilton; Susan M Goodman; Mark Figgie
Journal:  HSS J       Date:  2009-03-18

6.  Femoral resurfacing in young patients with hematologic cancer and osteonecrosis.

Authors:  Evguenia J Karimova; Shesh N Rai; Jianrong Wu; Lunetha Britton; Sue C Kaste; Michael D Neel
Journal:  Clin Orthop Relat Res       Date:  2008-08-05       Impact factor: 4.176

Review 7.  [Resurfacing for osteonecrosis of the femoral head].

Authors:  M Akbar; M A Mont; C Heisel; D R Marker; S D Ulrich; T M Seyler
Journal:  Orthopade       Date:  2008-07       Impact factor: 1.087

8.  Treatment of femoral head osteonecrosis in the United States: 16-year analysis of the Nationwide Inpatient Sample.

Authors:  Aaron J Johnson; Michael A Mont; Audrey K Tsao; Lynne C Jones
Journal:  Clin Orthop Relat Res       Date:  2014-02       Impact factor: 4.176

9.  Total hip arthroplasty in advanced osteonecrosis: the short-term results by metal-on-metal hip resurfacing.

Authors:  Firooz Madadi; Alireza Eajazi; Seyyed Morteza Kazemi; Armin Aalami Harandi; Firoozeh Madadi; Seyyed Reza Sharifzadeh
Journal:  Med Sci Monit       Date:  2011-02

10.  Long-term results of 32-mm alumina-on-alumina THA for avascular necrosis of the femoral head.

Authors:  Giuseppe Solarino; Andrea Piazzolla; Angela Notarnicola; Lorenzo Moretti; Silvio Tafuri; Silvana De Giorgi; Biagio Moretti
Journal:  J Orthop Traumatol       Date:  2012-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.